Study on QOL by severity in patients with atopic dermatitis
Not Applicable
- Conditions
- atopic dermatitis
- Registration Number
- JPRN-UMIN000051591
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Brief Summary
This study shows that atopic dermatitis severity impacts the quality of life in both adults and children. Specifically, skin QOL scores, DLQI and CDLQI, are closely linked with severity, suggesting that ongoing treatment for controlling severity improves QOL. No correlation was found between atopic dermatitis severity and TOPICOP score, indicating some patients have anxiety about topical steroids regardless of severity.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 1507
Inclusion Criteria
Not provided
Exclusion Criteria
None
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method DLQI EQ-5D-5
- Secondary Outcome Measures
Name Time Method Actual treatment situation and treatment adherence status TOPICOP WPAI:GH Sleep disturbances NRS Habitual scratching behavior Disease history CDLQI